Brokerages Set AC Immune SA (NASDAQ:ACIU) Price Target at $13.00

AC Immune SA (NASDAQ:ACIU) has earned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $13.00.

A number of research analysts have recently commented on the stock. ValuEngine raised shares of AC Immune from a “hold” rating to a “buy” rating in a research report on Friday, October 4th. HC Wainwright set a $8.00 price objective on shares of AC Immune and gave the company a “buy” rating in a research report on Friday, July 12th. Finally, BidaskClub lowered shares of AC Immune from a “hold” rating to a “sell” rating in a research report on Thursday, September 26th.

AC Immune stock traded up $0.08 on Friday, reaching $4.91. 1,661 shares of the stock were exchanged, compared to its average volume of 125,582. The firm has a fifty day moving average price of $5.13 and a two-hundred day moving average price of $5.19. The stock has a market cap of $331.04 million, a PE ratio of -5.82 and a beta of 0.06. The company has a current ratio of 21.90, a quick ratio of 21.90 and a debt-to-equity ratio of 0.01. AC Immune has a twelve month low of $3.25 and a twelve month high of $12.50.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.01. The business had revenue of $1.51 million during the quarter, compared to analyst estimates of $8.49 million. AC Immune had a net margin of 22.92% and a return on equity of 7.64%. Equities analysts anticipate that AC Immune will post 0.06 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in ACIU. Private Advisors LLC acquired a new position in shares of AC Immune during the first quarter valued at about $202,000. Marshall Wace North America L.P. raised its position in shares of AC Immune by 625.8% during the first quarter. Marshall Wace North America L.P. now owns 15,836 shares of the company’s stock valued at $80,000 after buying an additional 13,654 shares during the last quarter. Appleton Partners Inc. MA acquired a new position in shares of AC Immune during the second quarter valued at about $85,000. JPMorgan Chase & Co. raised its position in shares of AC Immune by 20.7% during the second quarter. JPMorgan Chase & Co. now owns 18,162 shares of the company’s stock valued at $99,000 after buying an additional 3,113 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of AC Immune during the second quarter valued at about $492,000. 26.75% of the stock is owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Recommended Story: Consumer Price Index (CPI)

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.